Byrnes Michael's most recent trade in CERo Therapeutics Holdings Inc. was a trade of 9,326 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on May 30, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| CERo Therapeutics Holdings... | Michael Byrnes | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 May 2025 | 9,326 | 9,326 | - | - | Stock Option (Right to Buy) | |
| CERo Therapeutics Holdings... | Michael Byrnes | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2025 | 17,923 | 17,923 | - | - | Stock Option (Right to Buy) | |
| CERo Therapeutics Holdings... | Michael Byrnes | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2025 | 127,500 | 255,000 | - | - | Stock Option (Right to Buy) | |
| CERo Therapeutics Holdings... | Michael Byrnes | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Dec 2024 | 127,500 | 127,500 | - | - | Stock Option (Right to Buy) | |
| eFFECTOR Therapeutics Inc | Michael Byrnes | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 1.68 per share. | 15 May 2024 | 1,387 | 3,117 | - | 1.7 | 2,334 | Common Stock |
| CERo Therapeutics Holdings... | Michael Byrnes | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Mar 2024 | 112,500 | 112,500 | - | - | Stock Option (Right to Buy) | |
| eFFECTOR Therapeutics Inc | Byrnes Michael | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Feb 2024 | 40,000 | 40,000 | - | - | Stock Option (Right to Buy) | |
| eFFECTOR Therapeutics Inc | Michael Byrnes | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.46 per share. | 15 May 2023 | 4,863 | 38,747 | - | 0.5 | 2,232 | Common Stock |
| eFFECTOR Therapeutics Inc | Michael Byrnes | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jan 2023 | 500,000 | 500,000 | - | - | Stock Option (Right to Buy) | |
| eFFECTOR Therapeutics Inc | Michael Byrnes | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.47 per share. | 15 Nov 2022 | 4,651 | 33,884 | - | 0.5 | 2,179 | Common Stock |
| eFFECTOR Therapeutics Inc | Michael Byrnes | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2022 | 235,541 | 235,541 | - | - | Stock Option (Right to Buy) | |
| eFFECTOR Therapeutics Inc | Michael Byrnes | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 1.33 per share. | 07 Jun 2022 | 25,000 | 29,233 | - | 1.3 | 33,263 | Common Stock |
| eFFECTOR Therapeutics Inc | Michael Byrnes | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 1.53 per share. | 13 May 2022 | 4,233 | 4,233 | - | 1.5 | 6,476 | Common Stock |
| eFFECTOR Therapeutics Inc | Michael Byrnes | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jan 2022 | 235,541 | 235,541 | - | - | Stock Option (Right to Buy) | |
| eFFECTOR Therapeutics Inc | Michael Byrnes | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Aug 2021 | 337,997 | 337,997 | - | - | Stock Option (Right to Buy) | |
| eFFECTOR Therapeutics Inc | Michael Byrnes | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Aug 2021 | 49,790 | 49,790 | - | - | Earn-out Right |